«The discovery of an alternative binding site and the AAPs represents a significant step towards the identification of a novel RNAP inhibitor that would behave like
rifampin but be devoid of any pre-existing resistance,» said Nader Fotouhi, Chief Scientific Officer at the Global Alliance for TB
Drug Development, a not - for - profit organization dedicated to finding faster - acting and affordable drug regimens to fight drug sensitive and resistant tuberculo
Drug Development, a not - for - profit organization dedicated to finding faster - acting and affordable
drug regimens to fight drug sensitive and resistant tuberculo
drug regimens to fight
drug sensitive and resistant tuberculo
drug sensitive and resistant tuberculosis.
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis
drug PA - 824 with concomitant lopinavir - ritonavir, efavirenz, or
rifampin.